In addition, the activated p38 MAPK levels were dramatically increased in the core area in response to cerebral ischemia compared to those in the sham-treated group, while the PCE-treated tMCAO group had markedly reduced levels of activated p38; these levels were decreased by about 80% and 40% compared to the vehicle-treated tMCAO group on days 1 and 3 post-stroke, respectively (Figure 7b–f). This evidence concerns the gene MAPK14 and Cerebral ischemia.